PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. UTILITY PATENT APPLICATION TRANSMITTAL
TO TO TO THE TRANSMITTAL
TO TO THE TRANSMITTAL

Attorney Docket No.	9196-019-999	Total Pages	
First Named	Inventor or Application	n Identifier a	。量
Jean-Louis Dasseux		00.	運
Express Mail Label No.	EL 451 596 906	S US	

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application	n contents.	Assistant Commissioner for Attention ADDRESS TO: Box Patent Application Washington, DC 20231
	l Pages <u>140</u>]	6. □ Microfiche Computer Program (Appendix) 7. ☒ Nucleotide and/or Amino Acid Sequence Submission
(preferred arrangement set forth below) -Descriptive title of the Invention -Cross Reference to Related Applications -Statement Regarding Fed sponsored R&D		 (if applicable, all necessary) a. □ Computer Readable Copy b. Ø Paper Copy (identical to computer copy)
-Reference to Microfiche Appendix -Background of the Invention	_	c. Statement verifying identity of above copies
-Brief Summary of the Invention -Brief Description of the Drawings (if filed) -Detailed Description of the Invention (including drawings)		ACCOMPANYING APPLICATION PARTS
- PA	s, if filed)	8. Assignment Papers (cover sheet & document(s))
-Abstract of the Disclosure		9. □ 37 CFR 3.73(b) Statement □ Power of Attorney (when there is an assignee)
3. Drawing(s) (35 USC 113) [Total	l Sheets 11]	10. □ English Translation Document (if applicable)
4. and Oath or Declaration [Total	ol Sheets 2]	11. Information Disclosure Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations
ẫ. □ Newly executed (original or copy)		12. ☐ Preliminary Amendment
(a) to Copy from a prior application (37 CFR 1.63(d)) (b) (for continuation/divisional with Box 17 completed)		13. ■ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
[Note Box 5 below] i. DELETION OF INVENTORS(S)		14. ☑ Applicant claims Small Entity status, see 37 C.F.R. § 1.27
Signed statement attached deleting inventor(s) na application, see 37 CFR 1.63(d)(2) and 1.33 (b).	med in the prior	15. □ Certified Copy of Priority Document(s) (if foreign priority is claimed)
5. Incorporation By Reference (useable if Box 4b is checked. The entire disclosure of the prior application, from which oath or declaration is supplied under Box 4b, is considered of the disclosure of the accompanying application and is incorporated by reference therein.	a copy of the ed as being part	16. □ Other:
17. If a CONTINUING APPLICATION, check appropriate box an ⊠ Continuation □ Divisional □ Continuation-in-par		site information: or application No: 09/465,719 filed December 17, 1999.
	RRESPONDENCE A	
Gustomes Number, 24041	No. or Attach bar	or □ Correspondence address below
NAME		
ADDRESS		
CITY	STATE	ZIP CODE
COUNTRY	TELEPHONE	FAX

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



Express Mail No.: EL 451 596 906 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Prior application:	Examiner Russell, J.	
* *		
	Art Unit 1653	

Assistant Commissioner for Patents Box PATENT APPLICATION Washington, D.C. 20231

Sir:

Į,

Street greet

This is a request for filing a ⊠ continuation □ divisional application under 37 CFR § 1.53(b), of pending prior Application Serial No. 09/465,719 filed on December 17, 1999.

Jean-Louis Dasseux, Renate Sekul, Klaus Buttner, Isabelle Cornut and Gunter Metz (inventor(s) currently of record in prior application)

or APOLIPOPROTEIN A-I AGONISTS AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS (title of invention)

1.

☐ The filing fee is calculated below:

PATENT APPLICATION FEE VALUE

ТҮРЕ	NO. FILED	LESS	EXTRA	EXTRA RATE	FE	E
Total Claims	14	-20	0	\$18.00 each	\$	0.00
Independent	2	-3	0	\$80.00 each	\$	0.00
			Basic Fee		\$	710.00
			Multiple Depo If Applicable	•	\$	270.00
			Total		\$	980.00
	50% Reduction for l Business Concern	Independent Invent	tor, Nonprofit Org	ganization or Small	- \$	490.00
			Total Filing	Fee	\$	490.00

- 2.
 ☐ Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.
- 3.

 Amend the specification by inserting before the first line the following sentence: This is a continuation of Application Serial No. 09/465,719, filed December 17, 1999.
- 4a.

 Transfer the drawings from the prior application to this application and abandon the prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.

PENNIE & EDMONDS LLP DOCKET NO. 9196-019-999	PENNIE &	: EDMONDS	LIP DOCKET NO	9196_019_000
--	----------	-----------	---------------	--------------

		PENNIE & EDMONDS LLP DOCKET NO. 9196-019-9
4b.		New formal drawings are enclosed.
4c.	×	Informal drawings are enclosed.
5a.		Priority of application no. filed on in is claimed under 35 U.S.C. §119.
5b.		The certified copy has been filed in prior application no., filed.
6.	×	The prior application is assigned of record to Esperion Therapeutics, Inc.
7a.		The Power of Attorney appears in the original papers in the prior application no., filed.
7b.	Ø	Since the Power of Attorney does not appear in the original papers, a copy of the Power in prior Application Serial No. 09/465,719, filed December 17, 1999 is enclosed.
8.	⊠	This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior Application Serial No.09/465,719, filed on December 17, 1999 be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from Application Serial No. 09/465,719 is enclosed.

- 9. The undersigned states, under 37 C.F.R. §1.821(f), that the content of the × enclosed paper Sequence Listing from Application Serial No. 09/465,719 is the same as the content of the computer readable form submitted in Application Serial No. 09/465,719.
- 10. Additional enclosures or instructions. Please enter the Preliminary \boxtimes Amendment canceling Claims 1, 16-18, 25, 33, 40 and 50 prior to calculating the fee.

Respectfully submitted,

Date: May 25, 2001

Rahul Pathak

(Reg. No.)

For: Laura A. Coruzzi (Reg. No. 30,742)

PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, N.Y. 10036-2711

(212) 790-9090